GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS
The review analyzes trials dealing with the safety of golimumab (GLM) used in rheumatology. This drug was the latest Contact: Galina Lukina;gvl3@yandex.ru Поступила 12.05.14tumor necrosis factor α (TNF-α) inhibitor introduced into clinical practice and therefore the estimation of its tolerability...
Main Authors: | G. V. Lukina, Ya. A. Sigidin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2015-04-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2076 |
Similar Items
-
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
by: B. S. Belov, et al.
Published: (2022-03-01) -
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis
by: Kuo-Tung Tang, et al.
Published: (2022-04-01) -
The Safety of Nicorandil Therapy and the Relationship with Treatment Adherence in Patients with Stable Angina Pectoris (According to the NIKEA Observational Study)
by: Yu. V. Lukina, et al.
Published: (2022-09-01) -
A report on the adverse events of special interest from the Romanian Registry of Rheumatic Diseases in patients treated with biologic and targeted synthetic disease-modifying anti-rheumatic drugs during 2022
by: Corina Mogosan, et al.
Published: (2023-12-01) -
Adverse events from the Romanian Registry of Rheumatic Diseases in patients treated with biologic and targeted synthetic disease-modifying anti-rheumatic drugs during 2019
by: Corina Mogosan, et al.
Published: (2020-03-01)